Matthew Deangelis

Matthew DeAngelis is an experienced leader in clinical operations with a focus on biopharmaceuticals and cell therapy. Currently serving as Associate Director of Clinical Operations at TG Therapeutics, Inc., Matthew has previously held similar positions at Immix Biopharma and Cabaletta Bio, where contributions included overseeing pivotal clinical programs for cell therapies targeting B-cell diseases and autoimmune conditions. Prior to these roles, Matthew managed clinical operations and studies at Seven and Eight Biopharmaceuticals and Merck, where responsibilities encompassed comprehensive clinical protocol execution and study management in both domestic and international settings. Additional experience includes roles in data sciences management and clinical development at CSL Vifor and Aspreva Pharmaceuticals. Matthew holds a Bachelor of Arts in Psychology from Rutgers University.